Elite neutralizers among HIV-1 Subtype-C infected individuals from southern India

Background: The isolation of broadly neutralizing antibodies has been a high priority since they were identified as potential targets for passive immunotherapy to slow or halt the disease progression in HIV-1 infected individuals. Until recently, only a few recombinant NAbs were available for clinical trials and requirement for the identification of broadly neutralizing sera from HIV-1 infected individual is still high. Although a few human...